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Future therapies targeted towards eliminating Candida biofilms and associated infections 
 
Abstract 
Introduction: Candida species are common human commensals and cause either superficial or 
invasive opportunistic infections. The biofilm form of Candida as opposed to its suspended, 
planktonic form, is predominantly associated with these infections. Alternative or adjunctive 
therapies are urgently needed to manage Candida infections as the currently available short 
arsenal of antifungal drugs has been compromised due to their systemic toxicity, cross-reactivity 
with other drugs, and above all, by the emergence of drug-resistant Candida species due to 
irrational drug use. 
Areas covered:  Combination anti-Candida therapies, antifungal lock therapy, denture cleansers, 
and mouth rinses have all been proposed as alternatives for disrupting candidal biofilms on 
different substrates. Other suggested approaches for the management of candidiasis include the 
use of natural compounds, such as probiotics, plants extracts and oils, antifungal quorum sensing 
molecules, anti-Candida antibodies and vaccines, cytokine therapy, transfer of primed immune 
cells, photodynamic therapy, and nanoparticles.  
Expert commentary: The sparsity of currently available antifungals and the plethora of proposed 
anti-candidal therapies is a distinct indication of the urgent necessity to develop efficacious 
therapies for candidal infections. Alternative drug delivery approaches, such as probiotics, 
reviewed here is likely to be a reality in clinical settings in the not too distant future. 
 
Key words: Alternative therapies, antifungals, Candida biofilm, candidiasis, antifungal resistance, 
immunotherapy, probiotics. 
  
Page 1 of 72
URL: https://mc.manuscriptcentral.com/eri   Email: dean.holland@informa.com
Expert Review of Anti-infective Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 2 
1. Introduction  
Candida is a dimorphic fungus commonly isolated as a member of the healthy human 
mycobiome (the fungal biota of the microbiome) of the gastrointestinal tract, oral cavity, skin and 
the vagina [1-4]. As residents of the mycobiome, they mainly coexist with bacteria, attached to 
either biotic or abiotic surfaces, essentially in the form of biofilms. However, when the host 
immunity is impaired, such as in HIV infection and AIDS, cytotoxic therapy, uncontrolled diabetes 
mellitus and in extremes of age (the very young and the very old) the healthy mycobiome shifts 
form a symbiotic existence with the resident flora, to a dysbiotic, pathogenic state [4]. Another 
reason for the dysbiosis is the prolonged use of broad-spectrum antimicrobials, when commensal 
Candida rapidly acquire pathogenic traits and cause a variety of infections ranging from 
superficial, mucosal (e.g. oral candidiasis) to haematogenously disseminated life threatening 
disease (e.g. candidemia) [5-7]. The incidence of Candida infections worldwide has been 
progressively rising over the last few decades mainly due to the significant increase in the 
population at risk, particularly, the spread of HIV, increased use of indwelling devices and 
immunosuppressive therapy [8].  
The magnitude of Candida infections is alarming. For instance, Candida species are ranked 
the fourth leading agent of health care associated infections globally [9] and carry the highest 
crude mortality rate of all nosocomial bloodstream infections, even exceeding those caused by 
Staphylococcus aureus and Pseudomonas aeruginosa [10]. The annual rates of incidence of 
Candida-associated nosocomial bloodstream infections at the beginning of this millennium 
ranged between 6.0 to 13.3, and 1.9 to 4.8 cases per 100 000 population in USA and Europe, 
respectively [11-15]. Hence ameliorating this disease burden is still a major healthcare priority, 
and the need for new antifungal therapeutic approaches rather urgent.    
Although over 150 of Candida species have been identified thus far, only 30 of them are 
known to be human pathogens [16-18]. Of these Candida albicans by far is the most virulent, 
predominant cause of human infection. Over 90% of all invasive candidiasis is caused by C. 
albicans together with four major non-albicans Candida spp.: Candida glabrata, Candida tropicalis, 
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Candida parapsilosis, and Candida krusei [19]. An upsurge of infections caused by, hitherto lesser 
known non-albicans Candida species such as Candida dubliniensis, Candida guilliermondii, Candida 
rugosa, Candida kefyr,   Candida famata and Candida auris has also been reported recently [20-
22]. 
 According to The National Institutes of Health of the United States of America, over 80% 
of all human microbial infections are associated with biofilms [23]. Microbial biofilms are defined 
as complex, structured, spatially oriented microbial communities that are encased in an 
extracellular matrix and attached to a surface. Candida species are known to build highly 
structured and dynamic biofilms comprising various morphological forms of the fungus (yeasts, 
pseudohyphae and hyphae, (Figure 1A) [24]. C. albicans, in particular, forms dense biofilms on 
indwelling devices such as catheters (urinary and central venous), joint prostheses, mechanical 
heart valves, pacemakers, contact lenses, and plastic dentures, resulting in significant morbidity 
and mortality [25,26].  
 The economic burden of Candida biofilms is alarming. In the United States alone, even with 
advanced therapies, over 100,000 annual deaths are reported due to catheter-associated Candida 
infections, costing over $6.5 billion in management [25,27]. The management of such device-
associated Candida biofilm infections remains extremely challenging due to the high rate of 
recalcitrance and the intrinsic resistance of   biofilms to antifungals. When these devices are so 
infested, high doses of antifungal agents together with the removal of the device has been 
recommended, which inevitably results in extensive and unnecessary tissue damage, serious and 
life threatening risks in critically ill patients as well as antifungal therapy associated adverse side 
effects, such as renal and hepatic damage [28-31]. Hence, the development of alternative or 
adjunctive therapies against Candida biofilm infections is an urgent necessity.  
 
2. Candida biofilm antifungal resistance 
The resistance to antifungals is one of the many characteristics acquired by Candida 
during its lifestyle transition from a free-floating planktonic state to a sessile/biofilm state. 
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Candida biofilms exhibits more than 1000-fold greater resistance to conventional antifungals 
compared to their planktonic counterparts [32,33]. During biofilm development Candida shows 
alterations in its resistance to antifungals as early as from the initial, surface adherence stage, 
reaching a peak resistance in mature biofilms [34]. Candida biofilm antifungal resistance is 
multifactorial and a number of well-coordinated, unique mechanisms appear to generate these 
highly recalcitrant robust biofilms. Some of these mechanisms are briefly outlined below.   
 
2.1 Biofilm cell density 
Biofilms are densely colonized with fungal cells. Several studies have suggested that the 
higher concentration of densely packed Candida blastopores with hyphal elements is likely to 
generate a high degree of antifungal resistance. Perumal et al [35] investigated the efficacy of 
several antifungal agents (azoles, amphotericin B and caspofungin) on a range of fungal cell 
concentrations from planktonic cultures, as well as disrupted biofilms. Their observations 
suggested that higher fungal cell densities offered greater resistance to experimented antifungal 
agents regardless of the origin of the cells. Hence, the effect was more physico-chemical in nature 
and not biofilm specific  [35]. 
 
2.2. Extracellular matrix 
It is now known that the extracellular matrix of Candida biofilms, mainly comprising 
carbohydrates (glucose, rhamnose, mannose, N-acetylglucosamine), proteins, phosphorous, 
hexamine, and uronic acid plays a critical role in modulating the biofilm lifestyle [36,37]. Apart 
from offering succor and support for Candida within the matrix to provide a structural scaffold, 
the extracellular matrix provides nutrients, hydration, enzymes, minerals, transport media for 
signaling molecules, and unfettered protection from external insults [38,39]. Though the exact 
mechanism/s is not yet clear, multiple theories have been proposed to explain the role of biofilm 
matrix in antifungal resistance.   
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 Al Fattani et al [37] observed a direct correlation between the degree of the production 
of extracellular matrix and the antifungal resistance in both C. albicans and C. tropicalis biofilms. 
Nett et al [40] investigated the role of extracellular matrix components of the biofilm in antifungal 
resistance and discovered a relationship between β-1,3 glucan content of the biofilms and 
fluconazole resistance. It appears that β-1,3 glucan inhibits fluconazole penetration into yeast 
cells either through drug binding or sequestration [40]. Similar observations for β-1,3 glucan-
antifungal interactions have been reported for amphotericin B, flucytosine and echinocandins 
[41,42]. Non-albicans Candida such as C. glabrata, C. tropicalis and C. parapsilosis biofilms have 
also been noted to employ similar matrix associated antifungal sequestration mechanisms [43]. 
Some credence to the latter hypothesis is provided by the fact that Candida biofilms display higher 
sensitivity to echinocandins, which inhibit the synthesis of matrix β-1,3 glucan [44].  
The relationship of C. albicans glucan synthase, and its genetic regulation has been further 
characterized with regards to antifungal resistant biofilm phenotypes [45,46]. These, studies 
however indicate that the potential of drug binding or sequestration is unlikely to contribute to 
the degree of drug resistance, as several folds higher concentrations of the antifungal (beyond that 
of the respective minimum inhibitory concentrations) could be found at the distal base of the 
biofilms. Others have proposed that, the antifungal effect could be better related to the rate of its 
diffusion through the matrix, than the final concentration of the drug [47]. 
Martins et al [48] have proposed that the presence of extracellular DNA (eDNA) may 
contribute to biofilm drug resistance. They noted a significant augmentation of antifungal activity 
of polyenes and echinocandins when candidal biofilms were treated with DNases, although this 
effect was not seen with fluconazole [48]. The exact role of eDNA in Candida biofilm antifungal 
resistance is yet to be determined. 
 
2.3. Drug efflux 
Upregulation of drug efflux pumps in microbial cell membranes are known to be 
associated with resistance to many antimicrobials by limiting their intracellular accumulation, 
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and hence, the potency of the drug [49]. Candida species possess two different categories of efflux 
pumps: The ATP binding cassette transporters (CDR1 and CDR2) and major facilitator transporter 
(MDR1) [50]. Usually, in the absence of external antifungal challenge, the expression and the 
activity of these pumps remains low [50]. Although upregulation of all three foregoing efflux 
pumps have been noted in azole resistant Candida particularly after long-term therapy of AIDS 
associated oropharyngeal candidiasis, their activity was insignificant in polyene and 
echinocandins resistance strains [51-53].  
The activity of drug efflux pumps in biofilms appear to be phase- and time-specific. Using 
mutant Candida strains, Ramage et al [54] noted that drug efflux pumps paly a substantive role in 
antifungal resistance of mature, rather than young biofilms (24-48h). On the contrary, Mukharjee 
et al [55] demonstrated that drug efflux pumps are predominantly responsible for the azole 
resistance in early biofilms (6h) of Candida [55]. In contrast, there is data to suggest that the mere 
attachment process of Candida to a surface is sufficient to trigger the upregulation of these efflux 
pumps and exposure to antifungals is not essential for their activation [56,57]. Similar efflux 
activities have been identified in non-albicans Candida species such as C. glabrata [58,59]. In 
addition, reports have indicated the presence of other potential efflux pumps, associated with 
fluconazole exposure e.g. those encoded by FLU1 [60]. These data indicate that drug efflux pumps 
play a role in drug resistance of Candida biofilms, contingent upon the antifungal in question.  
However, the drug efflux phenomenon is likely to be overshadowed by other dominant dug 
resistance mechanisms operational in biofilms, and may only partly contribute to the overall 
resistance.   
 
2.4. Modulation of sterol synthesis 
The composition of Candida cell wall sterol content significantly varies at different stages 
of biofilm growth. For instance, the cell membrane ergosterol content is lower  in Candida biofilms 
compared to planktonic counterparts, while established biofilms  have a lower ergosterol content 
(approximately 50% less) than  the early stage biofilms [55].  
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Candida in mature biofilms seems to utilize alternative approaches to maintain cell 
membrane fidelity, making them less favorable to ergosterol targeting drugs such as polyenes. 
Gene expression shifts may cause such alterations in the ergosterol content. ERG11 gene, for 
instance, which encodes an enzyme targeted by azoles, and ERG25 gene that plays a role in 
ergosterol demethylation leading to the synthesis of non ergosterol intermediates (e.g. eburicol 
and 14-dimethyl fecosterol) are significantly upregulated in mature biofilms [57]. Thus, the 
altered ergoster l biosynthestic pathway may itself confer a degree of drug resistance on Candida 
biofilms.   
 
2.5. Persister populations 
Persister cells are phenotypically variant subset of yeast cells that usually populate the 
basal and intermediate layers of biofilms that exhibit extremely high resistance to antimicrobial 
agents. Persister cells are common in both eukaryotic (Candida) biofilms as well as in prokaryotic 
(bacterial) biofilms [61,62]. Though the process of transition of regular biofilm cells to persister 
status is not clear, as yet,  it has been speculated that their metabolic dormancy might be 
responsible for the elevated antimicrobial resistance [63]. Modifications in Candida cell wall and 
the membrane structure may also contribute to persister cells development. This hypothesis is 
supported by the transcriptome analysis of persister population showing upregulation of genes 
responsible for ergosterol synthesis (ERG1 and ERG25) and β-1,6 glucan synthesis [64]. 
Up to 0.1-1% cells of the biofilm may consist of persister population, however, its 
concentration appear to be species and strain specifi [65]. For instance, C. albicans SC5314 strain 
is prone to form less persister cells than C. albicans GDH2346 [65]. Whereas C. glabrata does not 
form persister cells at all, compared with either C. albicans or C. krusei [65,66].  
Attempts to eradicate persister cell populations in candidal biofilms exposed to azoles 
have been made by Bink et al [67]. They reported that exposure of the biofilms to N,N’-
didiethyldithiocarbamate (DDC), an inhibitor of superoxide dismutase,  plays a major role in 
persister generation against azoles, and reduced the persister population by 18 fold  [67]. 
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Although persister phenomenon is unlikely to be the sole mechanism that confers antifungal 
resistance on Candida biofilms, their elimination is a promising objective that may help preclude 
yeast repopulation after successful antifungal therapy.   
 
2.6 Stress response 
  In general, microbial biofilms inhabit extremely hostile environments. Consequently, the 
biofilm microbe populations are exposed to a wide variety of internal and external stresses and 
insults. In response to such threats, these microbes have developed an array of stress responses, 
several of which have been identified in Candida biofilms., For instance, Kumamoto et al [68] 
demonstrated, using mutant strains that MAPK pathway, which maintains the cell wall integrity 
and contribute to filamentation of Candida, plays an important role in fluconazole resistance [68]. 
Mutant C. albicans strains of MKC1, which encode an important component Mkc1p in MAPK 
pathway, exhibited 100-fold less resistance to fluconazole [68].  
Similarly, a Ca2+ calmodulin-activated serine/threonine protein phosphatase, calcineurin, 
is associated with fluconazole resistance. Though the main function of calmodulin is to maintain 
cell homeostasis, morphogenesis and virulence, disruption of CNB1 or CRZ1 genes in calcineurin 
pathway led to increased susceptibility of Candida to fluconazole. When calcineurin pathway was 
blocked pharmacologically (using FK506), similar susceptibilities were observed suggesting the 
potential of calmodulin as a promising therapeutic target [69].  
Additionally, the heat shock protein 90 (HSP90) that is necessary for activation of 
calcineurin was identified to be important in Candida azole and echinocandins resistance [70,71]. 
An investigation of the potential of using HSP90 inhibitor together with fluconazole has shown 
that only 7 of 260 C. albicans strains tested developed resistance to fluconazole with either 
geldanamycin (HSP90 inhibitor) or FK506, suggesting another putative approach for tackling 
Candida biofilm antifungal resistance [72]. 
In summary, it is clear that the transition to biofilm lifestyle triggers a variety of cellular 
and molecular responses in Candida that is quite distinct from its planktonic counterpart. Thus 
Page 8 of 72
URL: https://mc.manuscriptcentral.com/eri   Email: dean.holland@informa.com
Expert Review of Anti-infective Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 9 
far, a number of mechanisms governing antifungal resistance in Candida biofilms, predicated by 
the stage of the biofilm development, as well as the specific Candida species and strains have been 
identified. However, the global linking mechanisms of these pathways and the triggers that 
activate such mechanisms remain to be clarified.     
 
3. Current armory of antifungals against Candida 
Human beings as well as fungi are eukaryotic organisms. This evolutionary resemblance 
of fungal and human cells severely restricts the number of drug targets that could be exploited for 
the development of antifungal agents [73,74]. Therefore, only a limited group of antifungal agents 
are currently available for managing Candida biofilm associated infections (Figure 2). These 
include polyenes, azoles, pyrimidine analogs, allylamaines, thiocarbamates, morpholines and 
echinocandins. The mode of action, toxicity, antifungal resistance mechanisms of these drugs are 
briefly outlined in Table 1.  
In general, azole antifungals, classic formulations of polyenes and the pyrimidine analogs, 
allylamines are not very effective against Candida biofilms [33,55,75,76]. In contrast, 
echinocandins, and lipid formulations of amphotericin B have displayed promising in vitro and in 
vivo potential against  Candida biofilms [44,77-80]. However, reports are emerging on the 
resistance of Candida biofilms to the newer  echinocandins [81]. Thus, total eradication of candidal 
biofilms with the pharmaceuticals available today remains a rather daunting challenge.   
 
4. Combined antifungal therapy 
Management of fungal infections via multiple antifungal administrations has been 
considered due to potential advantages over monotherapy. Antifungal multi-therapy benefits 
include: i) lower probability of antifungal resistance, ii) potential synergy of antifungal agents 
lowering the effective dose, duration and associated adverse effects; iii) broader spectrum of 
antifungal activity compared to a single agent; iv) improvements of fungicidal properties; and v) 
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inversion of selective pressure to disadvantaged drug resistant mutants and collateral sensitivity 
[82-85].   
Unlike with Cryptococcus and Aspergillus infections, attempts to investigate combined 
antifungal therapy against Candida infections appear to be limited. This is particularly due to the 
superior efficacy of existing agents such as polyenes and azoles against Candida infections. The 
Infectious Diseases Society of America (IDSA) in its latest guidelines have recommend that 
combination therapy should be avoided in treating invasive candidiasis as single agents are as 
effective as combined therapy [86].  
As mentioned above, the HSP90 inhibitors, which suppress heat shock protein 
contributing to drug induced stress response, have been evaluated using C. albicans biofilms. C. 
albicans catheter biofilm infection simulated in a rat model further proved that HSP90 inhibitors 
(e.g. 17-AAG) were capable of increasing the susceptibility of Candida (in catheter biofilms) to 
fluconazole, without any toxic effects [70]. In another in vivo study, when caspofungin was 
combined with HSP90 inhibitors, the survival of the murine litter infected with C. albicans 
improved significantly [87], suggesting the potential of HSP90 as a candidate agent for combined 
antifungal therapy against Candida biofilms.  
One of the well-known HSP90 client proteins, calcineurin has been receiving attention as 
a potential anti-fungal target due to its multiple roles in cell physiology such as cation 
homeostasis, cell cycle progression, virulence, cell morphogenesis and antimicrobial resistance 
[88,89]. Particularly, when azoles were combined with a calcineurin inhibitor, cyclosporin A or 
FK506, significant inhibition of Candida biofilms have been observed both in vitro and in vivo [69], 
suggesting the likely role of calcineurin in Candida biofilm antifungal resistance.  
Recently, there has been a resurgence of interest in developing combined antifungal 
therapy as the world is rapidly running out of potent agents not only due to the emergence of 
resistant strains but also due to the scarcity of effective drugs available. According to Antifungal 
Synergistic Drug Combination Database (ASDCD, http://asdcd.amss.ac.cn/), there appears to be 
virtually hundreds of candidate molecules and compounds that may present potential synergy or 
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additive effects with existing antifungal agents. Thus, combined antifungal therapy regimens are 
likely to be a reality sooner than expected in managing Candida biofilm-associated infections.    
 
5. Antifungal lock therapy 
  Candida species are the third leading cause of catheter-associated blood stream 
infections, and the agent for highest overall crude mortality for all nosocomial bloodstream 
infections [9].  Consequently the Infectious Disease Society of America (IDSA) has categorically 
recommended removal of the infected catheter, when associated with Candida [31]. These 
infections have many consequences. The removal and replacement of the infected catheter is 
likely to result in trauma as well as increased catheter-wound associated morbidity and mortality. 
Extremely high concentrations of antimicrobial agents are also necessary for eradicating 
refractory candidal biofilms within the luminal surfaces of catheters. This is particularly the case 
in situations requiring prolonged therapy in debilitated, bed-ridden patients with chronic 
illnesses. In order to prevent and improve outcomes of such catheter-related Candida infections, 
antifungal lock therapy (ALT) has been recently proposed. ALT entails installation of high 
concentrations of antimicrobial agents in a solution (‘lock’ solution) within the infected 
intravascular catheter for a prolonged period so as to ‘sterilize’ the catheter lumen [90-93].  
The potential of amphotericin B lipid complexes, and liposomal amphotericin B as lock 
therapy against C. albicans as well as, C. glabrata and C. parapsilosis has been shown in catheter 
biofilm models. Both of the foregoing amphotericin B preparations exhibited moderate efficacy in 
lowering biofilm viability, although, liposomal amphotericin B failed to eliminate mature 5-day 
old C. parapsilosis biofilms when exposed to a shorter lock period (<4h) [91,92]. This is likely to 
be due to the slow drug release mode of liposomal preparations. 
   Sequential exposure of C. albicans biofilms (on silicone disks) to sub-inhibitory 
concentrations of echinocandins followed by voriconazole or posaconazole was extremely potent 
in biofilm destruction [94]. To date however, the most promising anti-candidal biofilm effect has 
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been observed with lower concentrations echinocandins, together with liposomal formulations of 
amphotericin B [95,96].   
  Various other alternative agents have also been tested for their potency against Candida 
biofilms, essentially using in vitro models [93]. These include antibiotics such as doxycycline, 
vancomycin and tigecycline, and other chemicals such as heparin, streptokinases, lactoferrins, 
parabens, taurolidine, chitosan, EDTA, nonsteroidal anti-inflammatory drugs (NSAIDs, e.g. 
Aspirin) DNAses and ethanol [48,97-102]. In experimental studies all of the above agents, either 
alone or in combinations demonstrated moderate to strong fungicidal activity against C. albicans 
and non-albicans Candida biofilms on catheter luminal surfaces. These agents, however, remain 
to be exploited as potential antifungals for lock therapy.    
 There is limited information on antifungal lock therapy either in animal models or human 
clinical trials. In line with in vitro studies reported above, some have noted the superior efficacy 
of liposomal amphotericin B or echinocandins as antifungal lock therapy using a rabbit catheter 
infection model [103,104].  A few case reports indicate attempts to use, liposomal amphotericin 
B, caspofungin and ethanol as antifungal lock therapy against C. albicans, C. glabrata, C. 
parapsilosis, C. tropicalis, C. lipolytica and C. guilliermondii in catheter-related infections, although 
the rate of  failure was disappointing (as high as 100%,) particularly with liposomal amphotericin 
B [105-107]. These anecdotal reports, wanting of critical information such as pH, dosing intervals, 
the compatibility of the lock solutions, and the potential risk of precipitation of antifungals are 
inadequate to arrive at a final judgment on the in vivo efficacy of antifungal lock therapy in 
catheter-associated Candida biofilms. Hence further research on lock therapy is urgently required. 
  
6. Other potential approaches for combating Candida biofilms   
6.1. Denture cleansers 
In denture wearing elderly, the tissue fitting surfaces of unhygienic, acrylic (poly methyl 
methacrylate) denture surfaces may act as reservoirs of candidal biofilms and cause recalcitrant 
Candida-associated denture stomatitis [108].  Various denture cleansers have been evaluated for 
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their potential to eliminate Candida in denture reservoirs. However, there are only a few reports 
focusing on Candida biofilms as most deal with the initial phase of yeast adherence to denture 
surfaces.  Sodium hypochlorite (0.5-5.25%) was shown to be the most effective in killing adherent 
C. albicans and C. glabrata in some studies [109,110], despite the potential chemical damage 
hypochlorite may inflict upon the dentures, especially at higher concentrations. An enzyme based 
denture cleanser solution (Polident 3 Minute; GlaxoSmithKline, Philadelphia, USA) and another 
prepared from denture cleansing tablets (Corega Tabs; Block Drug Co, Jersey City, NJ) were found 
to effectively reduce the yeast burden in 72h Candida biofilms on acrylic denture materials despite 
their failure to remove the biofilm completely [111]. Similarly, various other commercially 
available cleansers e.g. Polident 3 min (GlaxoSmithKline, PA, USA), Efferdent, (Warner Lambert 
Co., NJ, USA), and cleansers with proteolytic/yeast lytic enzymes (e.g. Pika (Rohto Pharm Co, 
Japan), Liodent (Lion corporation, Tokyo, Japan), Dr. Hrealth (Sunstar Incorporation, Osaka, 
Japan), were also shown to have antifungal effects on adherent Candida, but not on Candida 
biofilms [112-114]. The active ingredients of these denture cleansers comprise   antimicrobial 
agents including EDTA, sodium bicarbonate, sodium perborate, hydrogen peroxide, and sodium 
hypochlorite, with varying degrees of antifungal activity.  However, an efficacious denture 
cleanser with anti-candidal biofilm activity remains to be elusive, as yet.  
 
6.2. Mouth washes 
Mouthwashes containing various active agents have been prescribed for daily use in 
reducing the microbial burden of the oral cavity, particularly in controlling dental plaque biofilms. 
In this context, the impact of commonly used mouth rinses on eradicating Candida biofilms has 
also been investigated. In in vitro studies, commercially available Corsodyl, Oraldene, and 
Listerine mouth rinses were found to reduce the viability of 48h C. albicans biofilms by 
approximately 80% [115]. The constituents of these mouthwashes are noteworthy.  Listerine 
(Pfizer Consumer Health Care, UK) contains eucalyptol, thymol, methyl salicylate, menthol and 
ethanol as active agents, while Oraldene (Warner-Lambert Consumer Health Care, UK) contains 
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hexetidine, and Corsodyl (GlaxoSmithKline Consumer Health Care, UK) contains chlorhexidine 
gluconate and ethanol.  
Similarly, another study has reported the superior efficacy of chlorhexidine gluconate 
(0.12%) and Listerine mouthwashes in eliminating Candida biofilms [116]. Interestingly, in a flow 
biofilm model of C. albicans, chlorhexidine appeared to be more effective in comparison to 
fluconazole and miconazole in reducing biofilm Candida [117].  
The duration of exposure to a mouthwash appears to have a critical impact on the 
substantivity and the consequent reduction of the biofilm cell density.  In a clinical trial, Tomas et 
al [118] noted that more than 60s exposure to chlorhexidine gluconate significantly improves C. 
albicans biofilm elimination, and the substantivity of the antiseptic. This said, most mouthwashes 
have significant undesirable side-effects including enamel staining, altered taste and a burning 
sensation (dysguesia), whilst the high alcohol content in some mouthwashes have been linked to 
mucosal pathology [119,120], These limitations of mouth washes detracts from their regular use 
in combating oral infections including candidal infestations.. 
 
6.3. Topical applications 
The potential of topical applications of antifungals in the management of Candida biofilms 
and related infections have been sparsely studied. Chlorhexidine gluconate gel as a topical 
adjunctive therapy for oral candidiasis seem to have benefits due to its prolonged antifungal effect 
(i.e. substantivity) permitting longer intervals of administration, thus increasing patient 
compliance [121]. Similarly, another study showed that the addition of chlorhexidine gluconate 
(0.2%) to tooth paste had favorable effect on reducing Candida colonization in HIV-infected 
children [122]. However, Candida regrew within 2-8 weeks after the termination of chlorhexidine-
laced toothpaste [122]. Nevertheless, the potential of topical applications of agents such as 
antiseptic gels and surface coatings for managing Candida biofilm infections is worth investigating 
further. 
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7. New anti-Candida therapeutics and promising future approaches 
Since the invention of amphotericin B in 1950s, only a handful of antifungal agents have 
been successfully introduced into the general consumer market for managing fungal infections. 
For instance, over the last three decades, echinocandins remain as the only novel antifungal drug 
class that was introduced by the pharmaceutical industry, and successfully adopted by clinicians.  
One major reason for this is the extreme challenge faced by the drug manufacturers when 
developing a new therapeutic agent, given the current stringent regulatory environment. Perhaps 
more importantly, in the case of antifungal agents, the challenge is magnified by the significant 
structural and functional similarities shared by the eukaryotic fungal cells and the human cells. 
This filial connectivity of humans and fungi drastically limits the number of drug targets in 
eukaryotic fungal cells that can be exploited for drug development leading to the current scarcity 
of antifungals available for the treatment of candidal infections [123].  
The current arsenal of antifungal drugs is further threatened by the increasing emergence 
of drug-resistant Candida species worldwide due to i) misuse of antifungals, ii) there limited 
spectrum of activity, iii) failure of biofilm elimination due to the largely fungistatic properties of 
the majority of drugs and iv) the significant toxicity of existing antifungal compounds [124]. 
Hence, alternative or adjunctive therapies are urgently warranted to control and prevent 
superficial and invasive Candida infections. A diversity of alternative antifungal therapies can be 
found in the literature to date and we feature below the most promising. 
 
7.1. Probiotics 
 Probiotics are defined as live microorganisms that, when administered or consumed in 
adequate quantities, confer health benefits on the host. A multiplicity of beneficial effects of 
probiotics are documented in the literature [125]. They are especially useful for combating 
pathologies of the gastrointestinal tract, such as relieving diarrhea, lactose intolerance and   
inflammatory bowel diseases [126]. 
Bacteria belonging to the genera Lactobacillus and Bifidobacterium are commonly used as 
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probiotics [126]. To be considered safe for human consumption, the probiotic microbe needs to 
be of human origin, and devoid of transmissible antibiotic resistance genes. Their functional 
requirements include adequate adherence and colonization on epithelial surfaces, acid and bile 
tolerances, immunostimulation, and antagonistic activity against pathogens [126]. 
The probiotics, mainly lactic acid bacteria, are deemed worthy as an alternative 
prophylactic and therapeutic agent for managing human candidiasis (Figure 1A and B) [127-129]. 
The efficacy of probiotics in relieving mucosal Candida infections has been extensively assessed 
in recent clinical investigations, vis a vis urogenital [130-133], gastrointestinal [127,134-136], and 
oral infections [137-141]. These studies demonstrate that probiotic bacteria (administration of 
either single or multiple strains) alone or in combination with standard antifungals (e.g. 
fluconazole) reduce candidal mucosal colonization, relieve signs and symptoms of candidiasis, 
and enhance the antifungal effect of conventional therapy. As these  randomized controlled trials 
substantiate the antifungal activity of probiotics in humans,  we believe that probiotics have 
potential therapeutic value  against Candida biofilms, [129]. Indeed, Matsubara et al [142] have 
noted, using a murine model, that the effects of probiotics may surpass even those of conventional 
antifungals in reducing experimental oral candidiasis. The anti-Candida biofilm potential of 
probiotics is both species and strain-specific and therefore the selection of a probiotic for 
therapeutic purposes needs to be carefully tailored to fit the specific clinical circumstances [143].  
Although the mechanisms of action of probiotics against Candida is unclear, as yet, the 
major attribute of probiotics appears to be the restoration of a natural healthy microbiome in a 
given habitat [129]. The re-establishment of a well-balanced and symbiotic state by probiotic 
bacteria, with suppression of Candida infection, may entail five distinct mechanisms: i) co-
aggregation of probiotic and fungal cells in order to impedes fungal colonization, ii) production of 
antagonistic antimicrobial and anti-biofilm compounds, iii) competing with the pathogen for 
available nutrients and adhesion sites, iv) production of quorum sensing chemicals that lead to 
down regulation of toxin production by the pathogens, and finally,  v) modulation of the humoral 
and cellular  immune system of the host (e.g.  subduing antibody  and phagocytic activity)[144]. 
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Clearly, stringent regulatory requirements need to be fulfilled prior to establishing a 
treatment protocol for a probiotic that is planned to replace traditional antifungal regimens. 
Initial, rigorous clinical trials are needed to ascertain the activity of the probiotic formulation, 
determine the dosage and administration schedules, and bio-dynamics, and side effects in 
humans. In the longer term, the potential for selection of resistant strains, mutability, and 
tolerability of the probiotic on prolonged use are also a concern due to the administration of live 
organisms. Despite these drawbacks probiotics remain a promising, yet to be fully explored, 
alternative therapeutic mode against biofilm associated candidal infections.  
 
7.1.1. -2-hydroxyisocaproic acid (HICA) 
Lactobacillus species are the most widely used probiotic bacterial species..  Its probiotic 
activity is thought to be mainly related to the production of 2-hydroxyisocaproic acid (HICA), an 
-hydroxy-amino acid [145]. The latter is found in human muscle and connective tissues and have 
protein synthetic and anti-inflammatory properties. Nieminen et al [145] investigated the effect 
of HICA on C. albicans biofilm formation and mutagenic acetaldehyde  production in vitro. The 
latter chemical produced by most Candida spp. is an important intermediary in candidal biofilm 
development. HICA was found to reduce biofilms of C. albicans, to a greater extent than 
capsofungin at acidic pH, and to inhibit acetaldehyde production. Using a murine C. albicans 
biofilm model, the same group found through histopathological examination that HICA attenuated 
inflammatory response, together with reduced expression of matrix metalloproteinase 9 (MMP-
9) and myeloperoxidase, both found in chronic inflammatory diseases and linked to the loss of 
soft and hard tissues [146]. This said, the precise mode of action for HICA is still unclear, and 
broader transcriptional and proteomic studies as well as in vivo studies are warranted to elucidate 
the mechanisms underlying its anti-microbial activity, and to evaluate its potential clinical use.  
 
7.2. Natural compounds 
A wide array of peptides and oils have natural antifungal activity [147,148] (Table 2). One 
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of these, saponins, produced by over one hundred plant families play a crucial role in defending 
the plants from extraneous microbial pathogens [149]. Coleman et al.[149] using a Caenorhabditis 
elegans model, identified 12 such saponins with antifungal capacity. Two of them at relatively low 
concentrations inhibited C. albicans isolates that were resistant to conventional antifungal agents. 
The precise mode of   action of saponins is not yet clear although they appear to adversely affect 
filamentation and biofilm formation - two central, virulence attributes of Candida. Saponins are 
also know to  bind to fungal ergosterol, and initiate pore formation in Candida cell membranes 
that lead to leakage of cellular contents and death.[149].  It has also been noted that saponins act 
synergistically with other antifungals, in vivo and enhance photodynamic fungal inactivation when 
combined with a photosensitizer [149].  
In a recent comprehensive study, Saleem et al [150] tested a polyphenol natural 
compound, lichochalcone-A, found in licorice roots of Glycyrrhiza species for its antifungal 
properties. This compound was found to significantly reduce Candida biofilm growth, even 
surpassing the effect of fluconazole, and decrease the proteinases and phospholipase activities of 
the yeast. The latter secretory enzymes play a significant role particularly in invasive candidal 
infections. In a time-kill assay, the fungal load was eradicated after 24 h, suggesting the potential 
efficacy of lichochalcone-A as a topical treatment. Further, in a mouse model of oral candidiasis, 
tongue tissues samples of lichochalcone-A treated litter presented with a lesser degree of 
infiltration and colonization of C. albicans compared with the control litter[150]. When the toxicity 
of this polyphenol was tested by the latter group, using a co-culture model of fibroblasts and 
Candida, no apparent toxicity was noted.  Thus lichochalcone-A appears to be a promising new 
agent effective against C. albicans biofilm associated infections, although much more work is 
required to fully characterize its activity [150]. 
Other plant-derived peptide that has anti-biofilm activity against Candida is Tn-AFP1 
[151,152]. This plant peptide purified from fruits of Trapa natans, inhibited C. tropicalis growth 
and disrupted biofilm formation in a concentration dependent manner, with no apparent adverse 
effect on red blood cells [151]. The latter workers noted Tn-AFP1 down regulated C. tropicalis, 
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MDR1 and ERG11 genes, both of which are associated with biofilm formation and drug resistance 
[151].  
Another novel, natural and cheap antimicrobial molecule that has been recently evaluated 
for its antifungal activity is carbohydrate-derived fulvic acid (CHD-FA), a derivative of humic acid 
[153,154]. This colloidal organic acid was found to be fungicidal in vitro against both planktonic 
and biofilm C. albicans. In one study, using an in vitro biofilm model, CHD-FA was noted to kill 92% 
of C. albicans after 24 h, including drug resistant strains, demonstrating its efficacious 
candidacidal potential [153]. The mechanism of its anti-candidal activity is yet unknown as the 
CHD-FA does not appear to adversely affect either the extracellular matrix production or its efflux 
pump activity. The low cost and broad-spectrum anti-biofilm activity of CHD-FA makes this 
natural compound a promising candidate agent worthy of further exploration. 
Furthermore, ApoEdpL-W peptide, a 18-amino-acid cationic, tryptophan-rich peptide 
derived from human Apolipoprotein E (ApoE), demonstrated fungicidal activity against C. albicans 
planktonic cells, but remained fungistatic at lower concentrations[152]. ApoEdpL-W was also 
active against early-stage C. albicans biofilms, but less active against mature biofilms, probably 
due to its affinity for extracellular matrix beta-glucans [152]. The mode of action of this 
antimicrobial peptide is not clear as yet, but it seems to act intracellularly at a vacuolar level 
through a process of endocytosis [152].  
Another category of natural products with antifungal properties that deserves attention 
is the tea polyphenols. In an in vitro study, three major polyphenol derivatives of green tea: 
epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), and epicatechin-3-gallate (EGC), were 
tested on their ability to nurture C. albicans growth and maintain a biofilm community [155]. 
Fungal biofilms incubated with any of these polyphenols for 48 h demonstrated a 72%, reduction 
of viable cells compared with untreated control cultures. Established biofilms treated with tea 
polyphenols were also significantly disrupted after 24 h of incubation. The mechanism of action 
of these natural extracts may include impairment of proteasomal activity, leading to cellular 
metabolic and structural disruptions that subdue biofilm formation in C. albicans [155]. The role 
Page 19 of 72
URL: https://mc.manuscriptcentral.com/eri   Email: dean.holland@informa.com
Expert Review of Anti-infective Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 20 
of tea polyphenols, if any, in therapy of fungal infections remains to be determined. 
The potency of essential oils derived from plants against Candida has been investigated 
for over three decades [156], However, it is only recently that  some have focused and partially 
succeeded in identifying new essential oils with a degree of antifungal activity [157,158]. 
Cinnamon oil, extracted from Cinnamomum especies, has been considered the most active out of 
a range of essential oils, showing candidacidal activity against both planktonic and biofilm 
cultures of Candida orthopsilosis and C. parapsilosis in [159], and clinical isolates C. albicans, C. 
glabrata, and C. krusei [157]. The fungicidal effect of essential oils may entail interference with the 
fungal cell wall development and structural modifications that render them susceptible. The 
hydrophobicity of these oils enable their close interaction with the lipid bilayer of fungal cell 
membrane, leading to  increased permeability, leakage of cell contents and death [160].  
Sesamol, a natural phenolic compound derived from sesame oil has been noted to be 
antifungal. One study investigating its mode of action noted that sesamol not only affects the cell 
membrane fluidity, but also inhibits yeast to hypha transition, biofilm formation,  mitochondrial 
dysfunction, and disruption of  iron transport, and DNA repair [161].  
Garlic (Allium sativum) has been traditionally used as an antimicrobial agent against a 
variety of microbes. The anti-Candida effect of garlic extracts have been examined and these 
include a wide range of ultrastructural perturbations affecting cytoplasmic membranes, 
organelles and cytoskeletal organization [162]. Further investigations into the candidacidal 
activities are now focused on the purified garlic constituents to determine the targets organelles 
that inhibit yeast growth. The garlic extract known as allyl alcohol, for instance, seems to mainly 
target cytosolically located, alcohol dehydrogenases Adh1 and Adh 2, and mitochondria based 
Adh3. A significant decrease in NAD(P)H after addition of allyl alcohol is indicative of another 
mechanism of its anti-Candida action. The effect of garlic or its extracts on candidal biofilms is yet 
to be determined. 
Natural products have the potential to be administered either alone or in combination 
with other antifungal drugs to combat C. albicans infections. In vitro tests have demonstrated 
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synergistic activity between natural compounds and conventional antifungal agents, such as 
amphotericin B, further reducing their minimal inhibitory concentrations (MIC) necessary to 
inhibit the biofilm formation of Candida spp. [163,164]. 
Clearly, the foregoing   indicates the array of natural anti-candidal agents that appear to 
be promising, and awaiting further investigations. However, they are yet to be comprehensively 
tested in human clinical trials, and the toxicities of many of the compounds are yet  to be evaluated 
[165]. Further clinical studies are urgently needed to establish the legitimacy of these rather 
promising natural compounds as alternative or supplemental therapies against biofilm associated 
Candida infections.  
 
7.3. Boric acid 
Boric acid (BA) is a versatile chemical that assists wound healing [166], and bone 
mineralization [167].   BA has also been used as an alternative therapeutic agent for recurrent 
vulvovaginal candidiasis [168]. Clinical studies that have compared fluconazole and BA in the 
management  of vulvovaginal candidiasis indicate  that it  is as effective as fluconazole in managing 
the condition, with the added advantages such as lower cost, ready availability and safety 
[169,170].   
The mechanism of action of BA against fungi is not yet understood, although some have 
suggested that it inhibits Candida filamentation [171]. Pointer et al have noted that the  selective 
inhibitory effect of BA on C. albicans hyphae is likely be due to the disruption of apical cytoskeletal 
elements of growing hyphae [172].  Well controlled large scale clinical trials are necessary to 
validate the use of BA against Candida infection in humans.  
 
7.4. Silver nanoparticles  
In the past decade or so, nanotechnology has emerged as a new paradigm that could be 
exploited for therapeutic drug delivery.  Perhaps the most promising antimicrobial nanomaterial 
thus far developed is the silver nanoparticles (AgNPs). When silver is in nanometric form (<10 
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nm), the larger total surface area is translated into higher surface reactivity that significantly 
enhances its antimicrobial activities with little toxicity [173]. As opposed to ionic silver, silver 
nanoparticles have potent, broad-spectrum antimicrobial activity with a well-tolerated tissue 
response, and no cytotoxic effects on either human fibroblasts or erythrocytes [174,175].  
AgNPs have shown fungicidal activity against Candida spp., including C. albicans, C. 
tropicalis, C. parapsilosis, and C. glabrata strains [157,174]. The stabilization of silver 
nanoparticles by surface-active agents (sodium dodecyl sulfate-SDS, Tween-80) or polymers 
(polyvinylpyrrolidone) significantly enhances its antifungal effects by increasing their aggregate 
stability [174]. This nano-sized inorganic material appear to act against fungal cells by disrupting 
the structure of the cell membrane and inhibiting the normal budding process due to the 
destruction of the membrane integrity [175]. When stabilized, with SDS, the nanoparticles, 
demonstrate augmented permeability of the cell wall and cytoplasmic membrane via bonding to 
its lipids and proteins.   
As Candida spp. are key colonizers, and play a major role in the formation of catheter 
lumen and other implant biofilms, the reduction or inhibition of Candida colonization on the 
surface of these medical devices, is a key to prevent recalcitrant infections (see above) [176].  
Hence, AgNPs have been suggested as a useful coating material for catheter luminal surfaces and 
medical titanium implants,  in order to reduce the biofilm burden, and to minimize the risk of 
infectious complications, and implant rejections [177,178].  
 
7.5. Immunotherapeutic approaches  
7.5.1. Vaccines 
   Vaccines against candidiasis appear to be a promising alternative against invasive 
infections [23]. Their preventive effect is based primarily on the reinforcement of 
immunogenicity, thus eliciting a stronger immune response [179]. Various fungal cell components 
have been explored as an active vaccine for disseminated and mucosal candidiasis (Table 3) [180]. 
We discuss below the major candidate vaccines currently being explored, namely fungal cell-wall 
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polysaccharide, proteins, and live attenuated fungal vaccines [179].  
 Animal studies by Saville et al [181] with, genetically engineered attenuated C. albicans 
tet-NRG1 strain vaccine, and then challenged with a fully virulent C. albicans CAF-2 strain,   
demonstrated significantly higher survival rates (100% more than the controls) of 
immunocompetent mice compared with their non-immunized litter mates [181]. These 
investigators tested the same vaccination strategy in immunocompromised animals (B-cell-
deficient, T-cell-deficient, and neutropenic DBA/2N mice) in order to determine the immune 
mechanisms involved. Vaccination fully protected B-cell-deficient and DBA/2N mice against 
disseminated candidiasis, but failed to protect the T-cell-deficient mice. Hence, the protection of 
the was conferred by a T-cell-mediated adaptive immune response, with little or no participation 
of B-cells and functional neutrophils [181]. Although promising, the presence of complex, poorly 
characterized antigens and  live attenuated C. albicans strains in this vaccine may have intrinsic 
clinical disadvantages [179].  
 Protein vaccines are potentially safer than attenuated live organisms. A variety of 
proteins, from the secreted aspartyl proteinase (SAP) family, and agglutinin-like sequence (Als) 
family, has already been tested with successful outcomes in pre-clinical trials, demonstrating a 
reduction of local and systemic infection by Candida spp. [179]. In a rat candidal vaginitis model, 
SAP vaccination (via intravaginal and intranasal routes) was found to promote fungal clearance 
in the vagina, with no fungi  3 weeks after the Candida challenge [182]. 
Furthermore, immunization of mice with recombinant N-Terminal Domain of Als1p 
(rAls1p-N) improved their survival on subsequent challenge with a lethal inoculum of C. albicans 
[183]. This study also suggested that the mechanism of action of the rAls1p-N vaccine is based on 
the stimulation of cell-mediated, rather than the humoral, response against C. albicans. 
 Glycoconjugates vaccines are another alternative for immunization against candidiasis. 
The conjugates of polysaccharide and a protein elicits a T-cell response, and have the potential to 
directly inhibit fungal growth [179]. Using a novel methodology, Xin et al [184] developed a fully 
synthetic glycopeptide vaccine against Candida by combining -mannan and a peptide epitopes. 
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The vaccine comprised six T cell peptides from Candida albicans cell wall proteins selected by 
algorithm peptide epitope searches and conjugated to the fungal cell wall -mannan trisaccharide 
[-(Man)3]. This vaccine showed protection against experimental disseminated candidiasis in 
mice. This vaccine differed from others in that it was likely to elicit a dual   immune response 
against both the glycan epitope as well as the peptide carrier. 
One key concern, and a major distraction for the proponents of vaccines against Candida 
infections is the generally held belief that disseminated candidiasis occurs almost exclusively in 
immunocompromised patients, who may not respond well to an active, as opposed to a passive, 
vaccination process. However, a recent study has allayed this concern as active immunizations 
with a peptide-pulsed dendritic cell vaccine protected neutropenic mice against disseminated 
candidiasis [185]. On the other hand, the same group found that the administration of monoclonal 
antibodies also protected the animals, implying the possibility of a passive immunotherapeutic 
strategy to protect against disseminated candidiasis [185].    
 The ideal vaccine against, either planktonic or biofilm Candida is yet to be developed. Cell 
wall proteins is likely to be a candidate antigen for inducing a protective host immune response, 
as most virulence attributes of Candida, including those involving adhesion, invasion, and the 
yeast-to-hypha transition, are associated with cell wall compounds [179]. The use of adjuvants, 
such as alum adjuvant, and dendritic cells as vehicles that present the vaccine to T cells are 
examples of tools that may enhance the immune response of the vaccine (Table 3) [180]. Although 
to date, most C. albicans vaccines are univalent, a multivalent vaccine with multiple unrelated 
antigens may also provide better protection against candidal infections [179].  
 Finally, up to now candidal vaccine technology has been limited to animal experiments 
and hence comprehensive clinical trials are urgently needed to demonstrate their efficacy and 
safety in humans. 
 
7.5.2. Anti-Candida antibodies 
 Anti-Candida antibodies are a yet another prospective avenue for immunotherapy [186]. 
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It has the potential for application in the treatment as well as prevention of candidiasis especially 
in immunocompromised patients. A human recombinant monoclonal antibody (Mycograb - 
NeuTec Pharma) against heat shock protein 90 (Hsp90) was investigated in a double-blind, 
randomized study in 139 patients with invasive candidiasis [187]. Combination therapy with the 
monoclonal antibody and amphotericin B led to a significantly better clinical and culture-
confirmed outcome compared with mono-therapy. A pre-clinical study testing the same antibody 
against Hsp90 t gether with caspofungin was also found be synergistic in another study  [188].  
 Other attempted therapeutic vaccine approaches include the use of  human recombinant 
antimannan immunoglobulin G3 (IgG3) monoclonal antibody derived from immune serum of  
mice vaccinated with Candida-mannan containing liposomes [189], and human recombinant anti-
mannan antibody G1 (igG1) [190], both of which were effective against disseminated candidiasis 
in mice. Worth mentioning also are anti--glucan antibodies induced by -glucan-conjugate 
vaccine [191], and idiotypic antibodies [192] which were effective experimental approaches 
against vaginal candidiasis in mice.  
 
7.5.3. Cytokine therapy 
 Cytokines play an important role in the host defense against infections and have been 
investigated as a useful tool for immunomodulation [186]. The adjunctive administration of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) was shown to promote clinical 
improvement with a reduction in mycological burden without adverse events in 
immunocompromised patients [193]. Another cytokine, interferon gamma (IFN), produced by T 
cells and NK cells, was found to increase anti-candidal potential of macrophages, although some 
have queried its efficacy [186]. In one study, the administration of IFN reduced the fungal burden 
in mice with disseminated candidiasis [194], but in another it failed to improve the potency of 
fluconazole against oral candidiasis in mice [195]. There is also a single clinical report of four 
patients, that has stated the beneficial contribution of IFN in patients with refractory fungal 
infections [196].  
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The literature on cytokine therapy for Candida infections is sparse and rather 
contradictory. Fuller, clinical trials with adequate patient numbers are necessary to validate the 
use of cytokine therapy as an adjunct in the treatment of candidiasis.  
 
7.5.4. Adoptive transfer of primed immune cells  
 Adoptive transfer of anti-fungal T cells has been attempted as an alternative 
immunotherapeutic approach to restore host immunity and as a cure for invasive fungal 
infections [197]. This approach utilizes infusion of patients with dendritic cells (DCs), primed ex 
vivo with antigens that induce specific cytokines, in order to induce an adaptive immune response 
[186]. These human T cells appear to inflict damage on the hyphal forms of Candida and also 
significantly boost the hyphal damage induced by human neutrophils [186]. The generated T cells 
do not seem to be impaired by cryopreservation. Hence, the anti-Candida T cells have the potential 
to be preserved, prior to the patient reaching an immune compromised state, to be subsequently 
infused if the infection is chronic and recalcitrant [198].  
 
7.6. Photodynamic therapy  
Antimicrobial photodynamic therapy (PDT) combines a non-toxic dye, a photosensitizer, 
added to microorganisms, which is activated by visible light of an appropriate wavelength, 
promoting a phototoxic response in the cells, usually leading to oxidative damage. This process 
essentially leads to disorganization of the cell wall as well as DNA damage, thus causing cell death 
[199,200].  
Different photosensitizers, both natural and synthetic, mostly belonging to the 
phenotiazinium, porphyrins or phthalocyanines classes, have been investigated for their utility as 
antifungals. A number of studies have demonstrated the efficacy of phenothiazine dyes such as 
methylene blue and toluidine blue in photodynamic therapy against Candida [199-203]. In a 
recent study, a glucosamine salt of a chlorine derivative soluble in water (Photodithazine - PDZ; 
a second-generation photosensitizer), and a light emitting diode (LED) light promoted significant 
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reduction in the viability of Candida isolates [202]. The same combination was also effective 
against treating mice with oral candidiasis [201]. 
The results of PDT may vary accordingly to the physiological state of the microorganisms 
as well as factors associated with the photosensitizer, such as the type, concentration, and period 
of incubation as well as the period of exposure and energy density of the laser [199]. In an in vitro 
study which investigated the effect of toluidine blue O (TBO) and 15 min of LED irradiation 
(energy density of 180 J/cm2) on the growth and adhesion of different Candida isolates to buccal 
epithelial cells  PDT  inhibited the adhesion of C albicans, C. tropicalis, and C. parapsilosis to buccal 
epithelial cells [203]. As the adhesion of Candida to host cells is an essential prerequisite for 
biofilm formation, colonization and infection, such regimens that inhibit Candidal adhesion may 
have useful translational potential.   
In summary, the novel approaches described above appear to be promising in eliminating Candida 
biofilms and associated infections. However, caution must be exercised when inferring their 
future potential due to the dearth of data from large scale, prospective clinical trials.   
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9. Expert commentary  
Microbial biofilms are robust structures that elicit extreme resistance to many 
antimicrobials, and Candida biofilms are no exception. Some of these resistance mechanisms are 
unique to the biofilm life style of the yeast while others they share with their planktonic 
counterpart. The common evolutionary resemblance between eukaryotic, fungal and human cells 
is yet another obstacle that impedes the development of anti-candidal agents. Further, most if not 
all, candidal infections are polymicrobial in nature. C. albicans, in particular, is known to build 
mixed species biofilms with other Candida species such as C. glabrata, C. tropicalis, C. dubliniensis, 
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C. parapsilosis, C. guillermondii, and C. krusei [25,204,205]. More importantly, they intimately 
interact and cohabit with various bacterial species in different host niches (e.g. oral cavity, vagina, 
gut). These include bacteria such as streptococcus mutans, Streptococcus gordonii, Actinomyces 
viscosus, and Fusobacterium species inhabiting the oral cavity [23,206,207], Enterococcus and 
Escherichia coli in the gastrointestinal tract, lactobacilli in the genital tract, and Pseudomonas 
aeruginosa in lung and wound infections [41,208-212]. Some of these interspecies and inter-
kingdom interactions, mediated particularly through quorum sensing mechanisms have been 
fairly well mapped [213]. 
 Up until now investigations on Candida biofilms have been hampered due to the lack of 
good in vitro and in vivo experimental systems. The introduction of high throughput biofilm 
models such as nano-biofilms is therefore a welcome addition to the armamentarium of biofilm 
biologists [214]. These studies should   focus on developing and redefining models that closely 
mimic the natural eco systems of bacteria and fungi.     
 The major drawback of the deficiency of drug targets in Candida can be overcome by 
identification of molecules that mediate yeast adhesion, regulation of persister formation, 
extracellular matrix secretion, and biofilm dispersal. These molecules may be useful in developing 
inhibitory substances that disrupt the biofilm life cycle. In addition, new approaches for drug 
penetration into biofilms are needed to further exploit the potential of existing antifungal agents 
and to minimise their side effects. One example being the echinocandins, that are considered the 
most efficacious against mature candidal biofilms, but are sparsely used due to their adverse 
effects [215,216].   
  Quorum sensing signalling molecules that are critical for the community life style of 
candidal biofilms, are likely to have considerable utility as anti-biofilm chemicals. Noteworthy 
here is the recently shown therapeutic benefits of inter-kingdom signalling molecules as biofilm 
disrupters, and antimicrobial adjuncts in eliminating  bacterial biofilms in the respiratory tract 
[217]. Similar approaches are worth investigating for managing Candida biofilm infections. In 
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addition, discovering new molecules that interfere with biofilm signalling pathways, as designer 
biomimetic molecules, would also be an attractive option. 
  Introduction of probiotics will likely to be one of the more promising approaches for 
eliminating biofilms. However, these probiotic organisms need to possess a very high safety 
margin, and optimization of their administration regimens is essential for long lasting anti-
Candida effect. Other unconventional approaches such as use of nanoparticles and plant products 
against candidal biofilms are also likely to deliver promising results.  
According to Antifungal Synergistic Drug Combination Database, many studies have been 
conducted in combining more than one active agent to achieve superior biofilm elimination to 
minimize side effects, and obviate emergence of drug resistance. These approaches, though 
promising, their utility in biofilm eradication is yet to be proven due to the scarcity of good 
experimental models that faithfully mimic the clinical environs. Finally, animal studies and long 
term human trials are critically important to establish the veracity and efficacy of any newly 
developed therapeutic regimens against candidal biofilms and these remain challenges due to the 
high developmental costs and the stringent regulatory environment. 
   
 
10. Five -year view 
Improvements in drug delivery systems as well as combination antifungal therapy are 
likely to advance the treatment regimens against local and systemic biofilm-associated Candida 
infections. In addition, the discovery of molecules that mediate Candida virulence and their 
exploitation as new drug targets will expand the antifungal armoury against Candida. Alternative 
therapies presented in this review, especially probiotics, are likely to be a reality, once there is 
satisfactory clinical database to support their use.  
 
11. Key Issues 
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 Candida is a dimorphic, opportunistic fungus/yeast commonly isolated as a member of the 
healthy human mycobiome. 
 Candida species can cause mild superficial infections to lethal systemic infections 
particularly in susceptible compromised hosts. 
 A significant portion of Candida infections are biofilm mediated, and exit in harmony with 
other bacteria and fungi, as highly specialised communities, encased in an extracellular 
matrix, and attached to either biotic or abiotic surfaces. 
 Biofilms exhibit extreme recalcitrance to conventional antifungal agents compared with 
the suspended, planktonic forms of the yeast. 
 The mechanisms that entail Candida biofilm antifungal resistance are complex and include 
biofilm specific mechanisms, such as the biofilm matrix associated factors and stress 
response, as well as those shared with their planktonic counterparts (e.g. drug efflux 
pumps and alterations in sterol synthesis). 
 Polyenes and echinocandins remain the most efficacious antifungals against Candida 
biofilms, while azoles are predominantly effective against the planktonic forms of the 
yeast.   
  Combinations antifungal therapy has had limited success in reducing drug toxicity and 
improving outcomes. 
 Antifungal lock therapy, proposed for catheter-related candidal infections may have 
potential utility against these infections. 
 Non-pharmaceutical approaches such as probiotics, silver nanoparticles and 
photodynamic therapy have also shown satisfactory activity against Candida biofilm 
formation and maturation, mostly in in vitro studies. 
 Recent studies have shown that natural compounds such as plants extracts and oils may 
help eradicate Candida biofilms with minimal undesirable effects. 
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 Modulations of the host immune response through anti-Candida antibodies, cytokine 
therapy and vaccines have all received considerable recent attention, but the results of 
these trials are inconclusive.   
 Most data generated on anti-Candida biofilm strategies are based on in vitro approaches. 
Thus, cautions must be exercised when extrapolating their applications for clinical use. 
 Further understanding of antifungal resistance mechanisms, identification of new drug 
targets and high throughput screening of potential therapeutic agents are necessary in 
combating Candida biofilm-related infections. 
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Table 1: 
Antifungal class Mode of action Adverse effects Resistance 
Polyenes 
e.g. amphotericin B and 
nystatin 
 Bind to the ergosterol in 
fungal cell membrane 
forming pores (Figure 2).  
 The pores compromise 
fungal cell wall integrity  
resulting ionic imbalance, 
intracellular contents loss 
and cellular death [218].  
 ‘Sterol sponge model’: 
polyenes (amphotericin B in 
particular) forms large 
extramembranous aggregate 
to extract ergosterol from the 
phospholipid bilayer, and 
sterol depletion in fungal cell 
membrane [219]. 
 
 Dose dependent toxicity, 
particularly, nephrotoxicity 
and infusion related 
adverse effects [220]. 
 Toxicity is due to the 
functional resemblance of 
fungal ergosterol to 
mammalian cholesterol 
leading to polyenes cross 
reactions [74]. 
 Liposomal formulations of 
amphotericin B were 
introduced to improve the 
safety margin [73,74]. 
 Candidal resistance to polyenes 
have been extremely rare. 
 Possible amphotericin B resistance 
in Candida is species dependent. C. 
glabrata and C. krusei exhibit 
higher minimum inhibitory 
concentration (MIC) to 
amphotericin B than C. albicans 
[221]. 
 C. lucitaniae, C. guilliermondii and C. 
glabrata have been identified to 
express resistant traits to 
amphotericin B [5]. 
 Polyene resistance could be due to 
the mutations of ERG3 and ERG6 
genes, resulting lower ergosterol 
contents in the cell membrane 
[222-224]. 
Azoles 
(2 subclassess) 
1. Imidazoles  
 Include miconazole, 
ketoconazole, 
clotrimazole, 
oxiconazole, econazole 
and tioconazole 
 Affect the cell membrane 
ergosterol by inhibiting its 
biosynthesis 
 Inhibits cytochrome P450 
14α-lanosterol demethylase 
encoded by ERG11 gene 
leading to suppression of 
 Azoles toxicity is rare 
 Nausea, minor 
gastrointestinal symptoms 
and asymptomatic 
transient hepatic enzyme 
elevations were reported 
[228]. 
 Azole resistance in oropharyngeal 
candidiasis in HIV infected 
patients is related to heavy 
overuse and fungistatic nature 
[229]. 
 Non-albicans Candida species e.g. 
C. glabrata, C. krusei and C. 
lucitaniae are intrinsically less 
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 Commonly prescribed 
for mucosal infections 
as topical applications 
2. Triazoles 
 Include fluconazole, 
itraconazole, 
posaconazole, 
voriconazole and 
terconazole 
 Prescribed for both 
tropical and systemic 
fungal infections 
[218,225,226] 
lanesterol to ergosterol 
conversion (Figure 2). 
 Severe reduction of the 
ergosterol in the cell 
membrane may also affect the 
“sparking” functions leading 
to altered cell proliferation 
and growth [51,52,218]. 
 suppression of cytochrome 
P450 14α-lanosterol 
demethylase lead the cell to 
bypass ergosterol synthesis 
and accumulate toxic 
methylated sterols that 
significantly affect membrane 
packing and elevates 
membrane fluidity (Figure 2). 
As a result, cell membrane 
undergo severe stress and the 
functions of various cell 
membrane proteins will be 
severely affected [227]. 
 
 Rare adverse effects 
include hypokalaemia, 
pedal oedema,  and 
testicular or adrenal 
steroidogenesis [228]. 
susceptible to fluconazole 
[230,231]. 
 Possible causes of resistance 
 Low intracellular drug 
accumulation due to 
Upregulation of drug efflux 
pumps coded by CDR1, CDR2 
and MDR1 
 Decreased target affinity due 
to mutation of ERG11 genes  
 Overexpression of ERG11  
 Inactivation of ERG3 gene to 
reduce accumulation of 
intracellular toxic sterols [232-
234]. 
 
Pyrimidine 
analogs/Fluoropyramidines 
 
E.g. 5-fluorocytosine (5-FC) 
and 5-fluorouracil.  
 Fluoropyramidines are 
synthetic structural analogs of 
the nucleotide cytosine 
 These analogs incorporate in 
to fungal nucleic acids during 
their synthesis and cause 
 Compared to 5-fluorouracil, 
5-FC results lesser side 
effects, though, serious 
adverse effects such as 
hepatotoxicity and bone 
 Resistance to 5-FC is rare (<2%) 
 Mainly due to the point mutations 
in FCY1 or FUR1 genes that encode 
cytosine deaminase and uracil 
phosphoribosyl transferase (Figure 
2). [224,238-240]. 
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either inhibition of DNA 
replication or synthesis of 
corresponding proteins 
(Figure 2) [235].  
marrow lesions have been 
reported [235-237].  
 
 Mutations of cytosine permease 
coded by FCY2 may also lower the 
uptake of the antifungal in to the 
cell (Figure 2) [238,240].  
Echinocandins 
e.g. caspofungin, micafungin 
and anidulafungin 
 Echinocandins are 
semisynthetic lipopeptides 
with a central cyclic 
hexapeptide structure [241]. 
 non-competitively inhibit a 
principal cell wall structural 
constituent, 1,3-beta-D-glucan 
(Figure 2) leading to  static 
destabilization of the fungus 
causing osmotic cell lysis 
[242,243]. 
 
 Echinocandins possess very 
low MIC resulting high safety 
margin [244,245].  
 Well tolerable with only mild 
side effects 
 Possible associations with 
hyperbilirubinaemia, acute 
renal failure, and haemolytic 
anaemia [246].  
 Hepatocellular tumors has 
been reported in animal 
models. 
 Recommended only when 
other antifungal agents are 
contraindicated [246]. 
 
 Candida resistance to 
echinocandins is low. 
 Echinocandin resistant C. albicans, 
C. glabrata, C. tropicalis and C. 
krusei have been reported [247-
250]. 
 C. parapsilosis, C. orthopsilosis, C. 
metapsilosis and C. guilliermondii 
are known to possess intrinsic 
resistance to echinocandins [251]. 
 
 Echinocandin resistance in Candida 
is caused by alterations of the (1,3)-
β-glucan synthase complex due to 
point mutations in FKS1 and/or 
FKS2 [252]. 
Allylamines, thiocarbamates, 
morpholines 
 Ergosterol synthesis 
inhibitors 
 Allylamaines and 
thiocarbamates inhibit 
squalene epoxidase coded by 
ERG1 gene 
 morpholines suppresses 
ERG24 encoded Δ7,8-
 Less commonly used in 
treating Candida spp. 
associated infections 
mainly due to their 
numerous adverse effects 
including gastrointestinal 
upset, taste disturbance, 
transient elevation of liver 
 Cross-resistance with azoles 
 Allylamines are used by CDR efflux 
pumps as substrates [255,256] 
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isomerase and ERG2 encoded 
C14-reductase (Figure 2) 
[226]. 
 
enzymes and liver toxicity. 
[226,253,254] 
 
Table 1: The classes, mode of actions, adverse effects of commonly used anti-Candida antifungals and Candida resistance mechanisms 
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Table 2 
 
Table 2: Antifungal activity of natural compounds against a variety of fungal strains  
 
 
 
Natural compound Origin Effective against Reference 
Saponins Different plant families C. albicans [149] 
Lichochalcone-A licorice roots of 
Glycyrrhiza species 
C. albicans [150] 
Carbohydrate- derived 
fulvic acid (CHD-FA) 
Humic acids (humic 
substances) 
C. albicans [153] 
Plant peptide (Tn-AFP1) Trapa natans fruits C. tropicalis  [151] 
Human peptide (ApoEdpL-
W) 
 
Human Apolipoprotein 
E  
 
C. albicans, C. 
parapsilosis, C. 
tropicalis, C. 
glabrata  
[152] 
Tea polyphenols Green tea C. albicans [155] 
Cinnamon oil Cinnamomum 
zeylanicum 
C. orthopsilosis and 
C. parapsilosis 
[159] 
Cinnamomum 
aromaticum 
(Cinnamomum cassia) 
C. albicans, C. 
glabrata, and C. 
krusei 
[157] 
Sesamol  Sesame oil C. albicans [161] 
Asarones  Acorus calamus  C. albicans and C. 
tropicalis  
[164] 
Garlic extract (Allyl 
alcohol) 
Allium sativum C. albicans [162] 
Acteoside (polyphenolic 
compounds)  
 
Colebrookea 
oppositifolia  
 
C. albicans, 
Cryptococcus 
neoformans, and 
Aspergillus 
fumigatus  
[163] 
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Table 3 
Vaccine targets Strategies to enhance Candida 
vaccines 
Heat-killed organisms Varied adjuvants  
Attenuated live organisms  Dendritic cell presentation  
Candida cell surface iC3b receptors  Virosome delivery 
Candida enolase DNA delivery  
Cell wall proteins Lipid particle delivery systems  
Candida mannans and -Glucans  Nasal delivery systems  
Heat-shock protein 90 (Hsp90)   
Glycosyl phosphatidylinositol (GPI)–anchor 
mannoprotein (Hyr1p) 
 
SAP and ALS genes family proteins   
 
Table 3. Entities explored for developing vaccines against local and disseminated candidiasis, and 
adjuvants and delivery systems proposed to boost Candida vaccine efficacy [Adapted from 
Edwards et al [180]. 
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Figure 1: The effect of probiotic lactobacilli on Candida albicans biofilms. Confocal laser scanning microscopic 
images (Stained with Live and Dead stain, Invitrogen, USA)  
A). Control C. albicans 24h biofilm; note the dense, spatially oriented structure that contains hyphae, 
pseudo hyphae and yeast cells. B) Lactobacilli treated C. albicans 24h biofilm; note the significant reduction 
of the density and the complexity of the biofilm with lower hyphal content compared to control.  
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Figure 2: Mechanisms of action of the antifungal classes currently used against   Candida   
5-FC: 5-fluorocytosine, 5-FU: 5-fluorouracil, 5-FUMP: 5-  fluorouridine monophosphate   
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Figures 
Figure 1: The effect of probiotic lactobacilli on Candida albicans biofilms. Confocal laser scanning 
microscopic images (Stained with Live and Dead stain, Invitrogen, USA) 
 A). Control C. albicans 24h biofilm; note the dense, spatially oriented structure that contains 
hyphae, pseudo hyphae and yeast cells. B) Lactobacilli treated C. albicans 24h biofilm; note the 
significant reduction of the density and the complexity of the biofilm with lower hyphal content 
compared to control. 
 
Figure 2: Mechanisms of action of the antifungal classes currently used against Candida 
5-FC: 5-fluorocytosine, 5-FU: 5-fluorouracil, 5-FUMP: 5-fluorouridine monophosphate 
Tables 
Table 1: The classes, mode of actions, adverse effects of commonly used anti-Candida antifungals 
and Candida resistance mechanisms 
Table 2: Antifungal activity of natural compounds against a variety of fungal strains  
Table 3: Entities explored for developing vaccines against local and disseminated candidiasis, and 
adjuvants and delivery systems proposed to boost Candida vaccine efficacy [Adapted from Edwards 
et al [180]. 
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Responses to Referee(s)' Comments. 
  
Referee 1: 
The authors review the role, prevention and treatment of biofilm in Candida infections, 
  
1) The manuscript is far too long and addresses numerous issues that are not directly relevant 
to biofilm and its role in candidiasis eg. Far too much attention to antifungal drugs and although 
penetration of antifungals into biofilm is important but not worth several pages on antifungals. 
 
Response: The antifungals section was significantly shortened and compiled in to a single table. 
(Section 3, page 9; and Table 1, page 32 -35). The title of the manuscript is amended to represent 
the content more precisely. 
 
All sections of the manuscript were edited to highlight the relevant information on Candida 
biofilms and related infections, particularly to stress their drug resistance, and therapies under 
development.  
  
2) The authors use “superlatives” all the time and often inappropriately. Moderation in language 
use will be useful. 
Response: We have reduced the use of superlatives throughout the manuscript as 
recommended.  
  
3) “The vast majority of Candida infections are biofilm mediated” – nonsense! Perhaps correct in 
relation to intravascular catheters, but mucosal (superficial) and invasive candidiasis much less 
relevant if at all. No evidence that Candida biofilm forming on urinary catheters is relevant 
except to explain persistence of Candiduria – catheters should be immediately removed once 
candiduria detected. 
 
Response: The particular statement was changed. Please see the introduction in the abstract 
(page 1) and under key issues (page 30) 
 
Nobile CJ and Johnson AD have reviewed the relationship of Candida biofilms with superficial, 
device-associated and systemic candida infections in “Candida albicans Biofilms and Human 
Disease” (Annu Rev Microbiol. 2015; 69:71-92.)  
 
4) What is the mycobiome as opposed to microbiome? 
 
Response: Mycobiome is the fungal biome in a specific niche such as the oral cavity or the gut, as 
opposed to bacteriome and the virobiome. 
 
 The following reference was added to the first paragraph of the introduction section (page 2). 
 
Please refer to “The human mycobiome in health and disease” By Cui L, Morris A, Ghedin E. 
(Genome Med. 2013 Jul 30;5(7):63.)  
 
5) Authors need to acknowledge that most of the data generated recently on biofilm is based 
upon in vitro models which have limitations and in vivo studies are lacking. 
 
Response: The limitations of the in vitro findings and the necessity of in vivo studies were stated 
at the end of Antifungal lock therapy (page 12), Probiotics (page 17), D,L-2-hydroxyisocaproic 
acid (page 18), and Natural compounds (page 21) sections.  
 
In addition, following statement was added to “key issues” 
 
Page 68 of 72
URL: https://mc.manuscriptcentral.com/eri   Email: dean.holland@informa.com
Expert Review of Anti-infective Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
“Key issues: Most data generated on anti-Candida biofilm strategies are based on in vitro 
approaches. Thus, cautions must be exercised when extrapolating their applications for clinical 
use. (Page 31) 
 
6) Many of non-pharmaceutical approaches have some value in vitro models only and are not 
relevant to clinical disease. 
 
Response: We agree with the reviewer, however, the aim of this review is to bring new 
therapies, products that have demonstrated anti-Candida properties with potential to be used 
against candidiasis in humans, even if they are in the early stage of development. 
 
The short arsenal of antifungal and the increasing emergence of drug-resistant Candida species 
give more credence for the development of adjunctive approaches that may be used as 
supplemental therapy.  
 
Hence the following clarification was added on Page 27: 
 
“In summary, the novel approaches described above appear to be promising in eliminating 
Candida biofilms and associated infections. However, caution must be exercised when inferring 
their future potential due to the dearth of data from large scale, prospective clinical trials.  (Page 
27)” 
 
  
7) Probiotics have never been shown to be useful in patient-related biofilm elimination or 
control. 
 
Response: The following clinical studies have demonstrated the capacity of probiotics alone or 
in combination with conventional antifungals to reduce oral colonization of Candida spp. in the 
oral cavity (1-5), urogenital track (6-8), and gastrointestinal track (9-11). Improvement of the 
clinical symptoms of candidiasis were also reported after administration of probiotic bacteria. 
These randomized controlled trials substantiate the antifungal activity of probiotics in humans, 
thus we believe that probiotics has the status of a future therapy against Candida biofilms. (The 
following studies have been already cited in the manuscript). 
 
1. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, 
Korpela R. 2007. Probiotics reduce the prevalence of oral candida in the elderly--a 
randomized controlled trial. J Dent Res 86:125-130. 
2. Mendonça FH, Santos SS, Faria Ida S, Goncalves e Silva CR, Jorge AO, Leao MV. 2012. 
Effects of probiotic bacteria on Candida presence and IgA anti-Candida in the oral cavity 
of elderly. Braz Dent J 23:534-538. 
3. Ishikawa KH, Mayer MP, Miyazima TY, Matsubara VH, Silva EG, Paula CR, Campos 
TT, Nakamae AE. 2015. A Multispecies Probiotic Reduces Oral Candida Colonization in 
Denture Wearers. J Prosthodont 24:194-199. 
4. Li D, Li Q, Liu C, Lin M, Li X, Xiao X, Zhu Z, Gong Q, Zhou H. 2014. Efficacy and safety of 
probiotics in the treatment of Candida-associated stomatitis. Mycoses 57:141-146. 
5. Kraft-Bodi E, Jorgensen MR, Keller MK, Kragelund C, Twetman S. 2015. Effect of 
Probiotic Bacteria on Oral Candida in Frail Elderly. J Dent Res 94:181S-186S. 
6. Martinez RC, Franceschini SA, Patta MC, Quintana SM, Candido RC, Ferreira JC, De 
Martinis EC, Reid G. 2009. Improved treatment of vulvovaginal candidiasis with 
fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-
14. Lett Appl Microbiol 48:269-274. 
7. Hu H, Merenstein DJ, Wang C, Hamilton PR, Blackmon ML, Chen H, Calderone RA, Li 
D. 2013. Impact of eating probiotic yogurt on colonization by Candida species of the oral 
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and vaginal mucosa in HIV-infected and HIV-uninfected women. Mycopathologia 
176:175-181. 
8. Kovachev SM, Vatcheva-Dobrevska RS. 2015. Local Probiotic Therapy for Vaginal 
Candida albicans Infections. Probiotics Antimicrob Proteins 7:38-44. 
9. Manzoni P, Mostert M, Leonessa ML, Priolo C, Farina D, Monetti C, Latino MA, 
Gomirato G. 2006. Oral supplementation with Lactobacillus casei subspecies rhamnosus 
prevents enteric colonization by Candida species in preterm neonates: a randomized 
study. Clin Infect Dis 42:1735-1742. 
10. Kumar S, Bansal A, Chakrabarti A, Singhi S. 2013. Evaluation of efficacy of probiotics 
in prevention of candida colonization in a PICU-a randomized controlled trial. Crit Care 
Med 41:565-572. 
11. Roy A, Chaudhuri J, Sarkar D, Ghosh P, Chakraborty S. 2014. Role of Enteric 
Supplementation of Probiotics on Late-onset Sepsis by Candida species in Preterm Low 
Birth Weight Neonates: A Randomized, Double Blind, Placebo-controlled Trial. N Am J 
Med Sci 6:50-57. 
 
8) It might be useful to separate biofilm occurrence on catheters etc (invasive candidiasis) from 
superficial candidiasis (oral and vaginal) since therapy would be entirely different! 
 
Response: The objective of this review is to evaluate current and potential future approaches to 
eliminate Candida biofilms and associated infections but not different clinical entities. Therefore, 
we have not separated Candida biofilm associated infections based on their clinical presentation 
to prevent potential repetition of the current and future approaches throughout the manuscript. 
 
9) No word on vaginal candidiasis and topical boric acid advocated as anti-biofilm. Major 
omission! 
 
Response: As mentioned in the response to comment 8, we refrained from discussing 
treatments/therapies based on the clinical presentation (vaginal, oral or gastrointestinal 
candidiasis) to avoid repetitions. However, different clinical variants of candidiasis were 
mentioned separately when necessary. Please refer to page 16 paragraph 2 – Probiotic section; 
page 24 paragraph 2 – Vaccines section. 
 
A new section about boric acid was included in the review (page 21 Section 7.3.) 
  
 
 
Referee 2: 
This is a comprehensive review of the literature on therapies targeted to Candida biofilm-related 
infections. Overall, it is a good and complete review of the available data. I have some comments 
below that need some attention by the authors. 
  
1. The drug efflux subsection should be re-written because the text does not always correspond 
to the indicated references (refs: 47-56). For example, ref. 53 (Lepak et al.,) concerns fluconazole 
activity against C. albicans planktonic cells, not biofilms. Ref 55 is a temporal global gene 
expression analysis of an in vivo Candida albicans biofilm, it is not about non-albicans Candida 
species. The conclusion of the particular subsection should also be re-phrased as authors 
conclude that efflux pumps play a significant role in antifungal resistance of C. albicans biofilms 
(pg 6; lines 42-43), but earlier on the authors state that the activity of efflux pumps was 
insignificant in polyene and echinocandins resistance strains (pg 6; lines 17-18). Furthermore, 
authors should exercise caution on generalizing about drug resistance, as most studies in the 
subsection concern data only on fluconazole resistance and there is one study on the activity of 
caspofungin against Candida displaying fluconazole resistance. It is not certain whether this is 
true for all azoles or all echinocandins. 
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Response: The drug efflux section has been extensively reviewed and the citation errors were 
corrected. 
  
Conclusion was amended as follows; 
 
“These data indicate that drug efflux pumps play a role in drug resistance of Candida biofilms, 
contingent upon the antifungal in question.  However, the drug efflux phenomenon is likely to be 
overshadowed by other dominant dug resistance mechanisms operational in biofilms, and may 
only partly contribute to the overall resistance.” (Page 6 penultimate paragraph) 
 
2. Ref 83 reports on the mode of action of antifungals and the mechanisms of drug resistance of 
Candida species without exploring drug resistance of biofilms. Therefore the statement 
“However, recent reports have indicate failure of fluconazole in eliminating Candida biofilm 
related infections” does not correspond to ref 83 (page 11, lines 27-28). 
  
Response: Entire section of “Current armory of antifungals against Candida” is now tabulated. 
Please see the response to first comment from the Reviewer 1 and particular reference was 
removed. (Section 3, page 9; and Table 1, page 32 -35) 
 
Correct references were added. Please see page 9 under the summarized section of “Current 
armory of antifungals against Candida”. (Section 3, page 9; and Table 1, page 32 -35) 
 
3. Section 3. “Current armory of antifungals against Candida” (pg 9-14) is mostly descriptive and 
concerns general knowledge on the mechanism of action of each reported drug and their 
effectiveness on various Candida species, but it does not contain any relevant information on the 
antibiofilm activity of these drugs. The section needs to be re-written in order to highlight 
information relevant to biofilm eradication. 
 
Response: Please see the responses to previous comment and first comment of the reviewer 1. 
(Section 3, page 9; and Table 1, page 32 -35) 
  
4. Same holds true for section 6. “Combined antifungal therapy”. This section, except for the 
Hsp90 inhibitors which have already been mentioned under the subsection of “Stress response” 
(pg 6, line 44), offers information on the use of combined antifungals as a strategy to combat 
Candida infections, but the particular section as well as the references provided are not specific 
to Candida biofilms (pg 14-15). 
 
Response: Particular section on “combined antifungal therapy” was refined to discuss anti 
biofilm approaches and nonspecific references were removed. (Pages 9-11) 
 
5. Subsection 7.2 needs to be part of 7.1 because HICA is also considered a probiotic. 
 
Response: The subsection 7.2 was shifted to 7.1.1 as a subsection of Probiotics section. (page. 
17) 
  
6. Section 7.5 (pg 27-32) refers to immunotherapeutic approaches as a strategy against invasive 
infections which is beyond the scope of this review. It is suggested to be eliminated. 
 
Response: We beg to differ. In our review we sought to bring the relevant proposed therapies 
against, both superficial and invasive candidiasis. For instance, candidate vaccines have shown 
some promise against superficial candidiasis (Extensively reviewed by Edwards et al 2012 Ref. 
180). Hence, in our opinion, the inclusion of immunotherapeutic approaches is relevant as a 
future therapy against Candida. 
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7. Several typos throughout the text 
 
Response: The text has been revised for typos. 
  
EDITOR’S COMMENTS: 
1. Please clearly hand sign the disclosure form, once you have filled it in (see attached). 
Response: Disclosure form was signed.  
 
2. Please confirm whether your figures and tables are original, or provide a copy of permission 
to use them. 
 
Response: We hereby confirm that all figures and tables are original.  
 
3. Please include some reference annotations in your end-text reference list (see attached guide). 
 
Response: Reference annotations were included.  
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